<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://healthandtechnow.com/articles/moderna-merck-melanoma-vaccine-interpath-001/</loc>
    <news:news>
      <news:publication>
        <news:name>Health and Tech Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-25T09:00:00-05:00</news:publication_date>
      <news:title>Moderna and Merck&apos;s melanoma vaccine cut recurrence or death by 42%, and Moderna stock fell 17.6%</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://healthandtechnow.com/articles/epic-prescription-marketplace-medicare-part-d-cash-price-cap/</loc>
    <news:news>
      <news:publication>
        <news:name>Health and Tech Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-24T20:05:00-05:00</news:publication_date>
      <news:title>Paying cash through Epic&apos;s new drug prices may not count toward Medicare&apos;s $2,400 cap</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://healthandtechnow.com/articles/centene-gold-card-unitedhealthcare-humana-cms-rule/</loc>
    <news:news>
      <news:publication>
        <news:name>Health and Tech Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-24T17:17:00-05:00</news:publication_date>
      <news:title>Centene&apos;s Gold Card vs. UnitedHealthcare and Humana</news:title>
    </news:news>
  </url>
  <url>
    <loc>https://healthandtechnow.com/articles/amgen-imdelltra-imfinzi-small-cell-lung-cancer-survival/</loc>
    <news:news>
      <news:publication>
        <news:name>Health and Tech Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-10-24T16:40:00-05:00</news:publication_date>
      <news:title>Amgen&apos;s Imdelltra with Imfinzi cut the risk of death by 58% in small cell lung cancer, a Phase 3 trial found</news:title>
    </news:news>
  </url>
</urlset>
